IN2014DN08266A - - Google Patents

Download PDF

Info

Publication number
IN2014DN08266A
IN2014DN08266A IN8266DEN2014A IN2014DN08266A IN 2014DN08266 A IN2014DN08266 A IN 2014DN08266A IN 8266DEN2014 A IN8266DEN2014 A IN 8266DEN2014A IN 2014DN08266 A IN2014DN08266 A IN 2014DN08266A
Authority
IN
India
Prior art keywords
treating
disease
receptor antagonist
viral
virus
Prior art date
Application number
Inventor
Altmeyer Ralf
Peijun Ren
Original Assignee
Inst Pasteur Shanghai Cas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Pasteur Shanghai Cas filed Critical Inst Pasteur Shanghai Cas
Publication of IN2014DN08266A publication Critical patent/IN2014DN08266A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a component and a method for treating a viral disease. A new use for a P2X receptor antagonist is disclosed for the first time said use being preparation of a composition for treating a viral infectious disease. The P2X receptor antagonist by means of inhibiting a virus can be used to prevent or treat hand foot and mouth disease.
IN8266DEN2014 2012-03-09 2013-03-11 IN2014DN08266A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210062620 2012-03-09
PCT/CN2013/072402 WO2013131496A1 (en) 2012-03-09 2013-03-11 Component and method for treating viral disease

Publications (1)

Publication Number Publication Date
IN2014DN08266A true IN2014DN08266A (en) 2015-05-15

Family

ID=49115954

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8266DEN2014 IN2014DN08266A (en) 2012-03-09 2013-03-11

Country Status (9)

Country Link
US (1) US9872875B2 (en)
EP (1) EP2875829A4 (en)
JP (1) JP6116596B2 (en)
KR (1) KR20150005526A (en)
CN (1) CN103301462B (en)
IN (1) IN2014DN08266A (en)
MY (1) MY169687A (en)
SG (1) SG11201405559TA (en)
WO (1) WO2013131496A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108014341A (en) * 2017-12-28 2018-05-11 南京东诺医药科技开发有限责任公司 Anti-inflammatory composition and its application
CN110064044B (en) * 2018-01-20 2022-09-09 中国科学院武汉病毒研究所 Enterovirus 71 inhibitor and application thereof
CN108553472A (en) * 2018-05-24 2018-09-21 南方医科大学 Applications of the NF546 in preparation multiple-effect microbicide and HIV spread through sex intercourse blocking agent
CN108685888A (en) * 2018-05-24 2018-10-23 南方医科大学 Applications of the NF023 in preparation multiple-effect microbicide and HIV spread through sex intercourse blocking agent
CN115211402A (en) * 2022-07-07 2022-10-21 中国医学科学院医学生物学研究所 Construction method and application of CV-B3 infected rodent model

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6280928B1 (en) * 1998-04-24 2001-08-28 Diagnostic Hybrids, Inc. Mixed cell diagnostic systems
ES2223287B1 (en) * 2003-08-04 2006-04-16 Universidad Del Pais Vasco-Euskal Herriko Unibertsitatea COMPOUNDS FOR THE TREATMENT OF DEMIELINIZING AND AUTOIMMUNE DISEASES.
HUP0500145A2 (en) * 2005-01-28 2006-11-28 Gene Res Lab N Use of o-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime for preparation of medicaments against oral diseases
AU2008337506A1 (en) 2007-12-18 2009-06-25 Glaxo Group Limited 5-oxo-3-pyrrolidinecarboxamide derivatives as P2X7 modulators
CN101780278B (en) * 2009-09-29 2012-02-01 福尔生物制药股份有限公司 Bivalent hand-foot-and-mouth disease inactivated vaccine
CN101695569A (en) 2009-11-03 2010-04-21 中国人民解放军军事医学科学院微生物流行病研究所 Univalent and bivalent gene engineered subunit vaccine for hand-foot-and-mouth disease and preparation method thereof
US8710079B2 (en) 2010-04-23 2014-04-29 National Health Research Institutes Quinoline compounds and their use for treating viral infection
US9051361B2 (en) * 2010-08-17 2015-06-09 National Health Research Institutes Immunogenic compositions and uses thereof
CN102178678B (en) * 2011-03-18 2012-12-19 中国医学科学院医学实验动物研究所 Application of lycorine in preparing medicament for treating diseases caused by human enterovirus 71 type infection

Also Published As

Publication number Publication date
US20150045318A1 (en) 2015-02-12
JP6116596B2 (en) 2017-04-19
EP2875829A1 (en) 2015-05-27
US9872875B2 (en) 2018-01-23
JP2015510870A (en) 2015-04-13
CN103301462A (en) 2013-09-18
EP2875829A4 (en) 2015-12-02
SG11201405559TA (en) 2014-11-27
KR20150005526A (en) 2015-01-14
MY169687A (en) 2019-05-13
CN103301462B (en) 2015-06-03
WO2013131496A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
PH12016500431A1 (en) Methods and pharmaceutical compositions for the treatment of hepatitis b virus infection
TN2013000485A1 (en) 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
MX358099B (en) Human immunodeficiency virus neutralizing antibodies adn methods of use thereof.
PH12015501003A1 (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
MD4589B1 (en) Pharmaceutical composition comprising sofosbuvir and uses thereof for treating hepatitis C virus
IN2014DN09173A (en)
MX2012009581A (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease.
MD4602B1 (en) Inhibitors of hepatitis C virus
EA201590358A1 (en) Inhibitors of Human Immunodeficiency Virus Replication
MY168959A (en) Vaccine compositions for the prevention of dengue virus infection
PH12014502875A1 (en) Vaccine compositions for prevention against dengue virus infection
PH12015502230A1 (en) Novel viral replication inhibitors
HRP20190393T1 (en) An antibody composition for prevention or treatment of mutant hepatitis b virus infection
PH12016501968A1 (en) Novel macrocyclic compounds
IN2014DN08266A (en)
MX2013012233A (en) Substituted 4-aryl-n-phenyl-1,3,5-triazin-2-amines.
EP2893936A4 (en) Method and agent for the treatment and prophylaxis of diseases caused by (+)rna-containing viruses
BR112014003989A2 (en) compound, compositions and methods for inhibiting hiv-1 replication in a patient, for treating HIV-infected patients and for pre-exposure prophylaxis for treating the patient and for preventing transmission from infected to uninfected person
MY171497A (en) Crystalline forms of dihydropyrimidine derivatives
ZA201307019B (en) Compositions for preventing and/or treating and infection by an hiv-1 virus
IN2011CH03893A (en)
EA019080B9 (en) Alpha-crystalline form of carbabenzpyride
NZ625532A (en) Compositions and methods for treating hepatitis c virus